Indeed, a single IT administration of TransCon TLR7/8 Agonist was sufficient to induce robust and persistent anti-tumor activity, while also inducing significantly lower systemic cytokine/chemokine release compared to administration of soluble resiquimod. Here, TLR7 is linked to neoplasm.